Wendan Xu

Muenster, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Analysing open-source protein folding models for nanobody binding prediction.

Analysing open-source protein folding models for nanobody binding prediction.

Journal: Frontiers in bioinformatics

Published: April 17, 2026

Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma.

Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma.

Journal: Leukemia

Published: February 15, 2024

Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress.

Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress.

Journal: Blood advances

Published: June 13, 2023

Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas.

Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas.

Journal: Blood

Published: June 09, 2023

Atomically Dispersed FeN2 P2 Motif with High Activity and Stability for Oxygen Reduction Reaction Over the Entire pH Range.

Atomically Dispersed FeN2 P2 Motif with High Activity and Stability for Oxygen Reduction Reaction Over the Entire pH Range.

Journal: Angewandte Chemie (International ed. in English)

Published: May 28, 2023

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.

Journal: Frontiers in immunology

Published: May 10, 2023

Transcriptional reprogramming by mutated IRF4 in lymphoma.

Transcriptional reprogramming by mutated IRF4 in lymphoma.

Journal: Nature communications

Published: November 29, 2022

mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma.

mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma.

Journal: Leukemia

Published: June 17, 2022

Metal-Organic Frameworks for Ion Conduction.

Metal-Organic Frameworks for Ion Conduction.

Journal: Angewandte Chemie (International ed. in English)

Published: May 03, 2022

GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia.

GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia.

Journal: Leukemia

Published: February 10, 2022

Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.

Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.

Journal: Leukemia

Published: November 05, 2021

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.

Journal: Blood

Published: December 07, 2020

Showing 1-12 of 17

Last Updated: 09/26/2026